Prevalence of C-Reactive Protein Elevation and Time Course of Normalization in Acute Pericarditis

Massimo Imazio, Antonio Brucato, Silvia Maestroni, Davide Cumetti, Antonio Dominelli, Giuseppe Di Natale, Rita Trinchero

Circulation · 2011 · 182 citations · 8 references

DOIFull text

Open access

Concepts

TL;DR

Inflammatory markers are poorly defined for diagnosing or treating pericarditis. This study prospectively assessed how often high‑sensitivity C‑reactive protein (hs‑CRP) is elevated in acute pericarditis, its normalization timeline, and its diagnostic, therapeutic, and prognostic relevance. We measured hs‑CRP at presentation and weekly thereafter in 200 consecutive viral or idiopathic acute pericarditis patients followed from 2005 to 2007 at two Italian referral centers. Hs‑CRP was elevated in 78 % of patients, normalized in 60 % by week 1, 85 % by week 2, 95 % by week 3, and all by week 4, and elevated hs‑CRP at week 1, incomplete response to therapy, and corticosteroid use independently predicted recurrence, indicating hs‑CRP can identify high‑risk patients and guide therapy duration.

Abstract

Background— The role of inflammatory markers is not well defined for either diagnosis or treatment of pericarditis. The aim of this study is to prospectively evaluate the frequency of high-sensitivity C-reactive protein (hs-CRP) elevation in patients with acute pericarditis, its time course of normalization, and the possible importance for diagnosis, therapy, and prognosis. Methods and Results— Two hundred consecutive patients with viral or idiopathic acute pericarditis (mean age, 53±15.5 years; 103 men) were studied from August 2005 to August 2007 in 2 Italian referral centers. Hs-CRP was determined at presentation and then every week until normalization. Hs-CRP elevation was recorded in 156 of 200 cases (78%) at presentation. Recognized causes of a negative hs-CRP at presentation were early assessment in 15 of 44 cases (34%) and previous anti-inflammatory therapies in 22 of 44 cases (50%). Hs-CRP normalization was achieved with the following time course: 120 of 200 (60%) at week 1, 170 of 200 (85%) at week 2, 190 of 200 (95%) at week 3, and all cases (100%) at week 4. In multivariable analysis, incomplete response to empirical anti-inflammatory therapy at week 1 (hazard ratio, 2.98; 95% confidence interval, 1.80 to 4.94; P <0.001), corticosteroid therapy (hazard ratio, 2.80; 95% confidence interval, 1.59 to 4.95; P <0.001), and the presence of elevated hs-CRP at week 1 (hazard ratio, 2.36; 95% confidence interval, 1.32 to 4.21; P =0.004) were independent risk factors for recurrence. Conclusions— Hs-CRP is elevated at the initial presentation in ≈3 of 4 cases of acute pericarditis, identifies patients at higher risk of recurrence, and could be used to monitor disease activity and select appropriate therapy length.

References

8